In 2024 alone Freya Biosciences announced a $10 million investment, Kanvas Bio unveiled clinical data on anti-tumoral immunity impact, EnteroBiotix advances cirrhosis, the FDA allowed OpenBiome’s FMT investigation to continue, and Nexilico and Siolta Therapeutics enter collaboration for necrotizing enterocolitis. Despite funding challenges in the past few years, as microbiome awareness increases and new preclinical and clinical data emerges, the microbiome community remains committed to proving the microbiome potential to treat patients across many therapeutic areas.
Guiding the strategic direction of the agenda from an industry and investor perspective, and leading the awards ceremony, our esteemed Scientific Advisory Board includes:
Ken Blount,
Chief Scientific Officer,
Rebiotix Inc.,
a Ferring Company
Denise Kelly,
Investment Advisor, Seventure Partners
Jessica Schneider,
Chief Scientific Officer,
Corundum Systems Biology
Nikole Kimes,
Founder & Chief Executive Officer,
Siolta Therapeutics
Daniel Couto,
Chief Operating Officer,
Vedanta Biosciences
What’s New for 2025?
Celebrate the 10th Anniversary Awards:
Join us in honoring a decade of groundbreaking achievements in microbiome research with special awards recognizing exceptional contributions and innovations in the field.
Introduce New Speakers:
Gain fresh insights from newly added experts representing companies such as Pulmobiotics, Kanvas Biosciences, and Azitra.
Showcase New Companies:
Discover the latest advancements from emerging companies like Alveolus Bio, Microviable Therapeutics, Unilever, Mikrobiomik, Jona, and Nestle Health Science, each presenting their innovative approaches in microbiome research.
Engage with Investors:
Participate in the startup showcase, featuring an expert panel of leading investors and venture capitalists like Seventure Partners and CSB, as they evaluate and support the next generation of microbiome startups.
Join Your Peers to:
Innovative Approaches in GI & Infectious Diseases
Explore the latest advancements in gastrointestinal microbiome treatments with Ferring Pharmaceuticals, and discover innovative approaches to enhance treatment efficacy and reduce toxicity with Microviable Therapeutics and MRM Health.
Predictive Diagnostics in Microbiome Research
Hear from Dare Bioscience on the impact of vaginal products on the vaginal microbiome and their regulatory insights, and explore Jona's AI-driven analytics to match strain selection with patient response, enhancing the selection process for targeted treatments.
Preclinical & Translational Models for Microbiome Therapies
Investigate the integration of in vivo and ex vivo models with Kanvas Bio to enhance drug efficacy assessments, and hear from Mbiomics on strategies for controlled manufacturing of complex microbial consortia.
Next-Gen Therapeutics
Discuss efficacy considerations with insights from MD Anderson Cancer Center and Nestlé Health Science into the development of next-gen therapies that retain their efficacy while improving delivery and reducing side effects for treating various health conditions.
Future of Microbiome Research
Engage with Seres Therapeutics and BiomeBank in a forward-looking dialogue on the evolving landscape of microbiome research, highlighting the role of innovative therapies in clinical validation and the shift towards more patient-centric approaches in treatment strategies.
Who Will You Meet?
